已故肾脏供者血清中Syndecan-1作为肾脏功能的潜在生物标志物

IF 0.8 4区医学 Q4 IMMUNOLOGY

Transplantation proceedings Pub Date : 2025-01-13 DOI:10.1016/j.transproceed.2024.12.031

Pavel Navratil , Sukhdeep Sahi , Petra Hruba , Alena Ticha , Katarina Timkova , Ondrej Viklicky , Vladimir Cerny , David Astapenko

{"title":"已故肾脏供者血清中Syndecan-1作为肾脏功能的潜在生物标志物","authors":"Pavel Navratil , Sukhdeep Sahi , Petra Hruba , Alena Ticha , Katarina Timkova , Ondrej Viklicky , Vladimir Cerny , David Astapenko","doi":"10.1016/j.transproceed.2024.12.031","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The process of kidney transplantation remains the optimal treatment for end-stage renal disease, offering improved quality of life and increased survival rates compared to long-term dialysis. However, despite advances in surgical techniques, immunosuppression regimens, and post-operative care, there are still significant challenges in predicting the organ's status and long-term outcomes of transplantation. Among the many factors that influence graft survival, the quality of the donated organ plays a fundamental role. There is an ongoing need for accurate and reliable biomarkers. Syndecan-1 is found in the endothelial glycocalyx and shed at a higher rate into the blood during systemic pathological conditions. The aim of this study is to evaluate the potential of serum syndecan-1 levels as a biomarker for assessing donor kidney quality and to investigate its correlation with donor characteristics and short-term outcomes in kidney recipients.</div></div><div><h3>Material and Methods</h3><div>We investigated serum syndecan-1 levels in 80 deceased donors and correlated them with donor characteristics and short-term outcomes (defined as delayed graft function - defined as the need for dialysis within the first week post-transplantation and renal function at 3 months post-transplantation - assessed using serum creatinine levels) in 104 corresponding kidney recipients. This single-center retrospective observational cohort study was conducted from April to December 2021.</div></div><div><h3>Results</h3><div>The donor pool consisted of 65% males with a median age of 53 years. Of these, 45 donors (56%) were classified as extended criteria donors. Higher syndecan-1 levels correlated with the last creatinine levels before organ procurement (<em>R</em> = 0.32, <em>p</em> = 0.01) and were marginally higher in donors with acute kidney injury (<em>p</em> = 0.07). However, syndecan-1 levels were not associated with short-term outcomes in kidney recipients (renal function at 3 months).</div></div><div><h3>Conclusions</h3><div>The data suggests syndecan-1 could be a potential biomarker for assessing donor kidney quality, although its implications on recipient outcomes require further study. This pilot investigation underscores the importance of syndecan-1 in evaluating organ quality but highlights the necessity for more extensive research to validate these findings and explore their implications in transplant success.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 2","pages":"Pages 187-193"},"PeriodicalIF":0.8000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Syndecan-1 in the Serum of Deceased Kidney Donors as a Potential Biomarker of Kidney Function\",\"authors\":\"Pavel Navratil , Sukhdeep Sahi , Petra Hruba , Alena Ticha , Katarina Timkova , Ondrej Viklicky , Vladimir Cerny , David Astapenko\",\"doi\":\"10.1016/j.transproceed.2024.12.031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The process of kidney transplantation remains the optimal treatment for end-stage renal disease, offering improved quality of life and increased survival rates compared to long-term dialysis. However, despite advances in surgical techniques, immunosuppression regimens, and post-operative care, there are still significant challenges in predicting the organ's status and long-term outcomes of transplantation. Among the many factors that influence graft survival, the quality of the donated organ plays a fundamental role. There is an ongoing need for accurate and reliable biomarkers. Syndecan-1 is found in the endothelial glycocalyx and shed at a higher rate into the blood during systemic pathological conditions. The aim of this study is to evaluate the potential of serum syndecan-1 levels as a biomarker for assessing donor kidney quality and to investigate its correlation with donor characteristics and short-term outcomes in kidney recipients.</div></div><div><h3>Material and Methods</h3><div>We investigated serum syndecan-1 levels in 80 deceased donors and correlated them with donor characteristics and short-term outcomes (defined as delayed graft function - defined as the need for dialysis within the first week post-transplantation and renal function at 3 months post-transplantation - assessed using serum creatinine levels) in 104 corresponding kidney recipients. This single-center retrospective observational cohort study was conducted from April to December 2021.</div></div><div><h3>Results</h3><div>The donor pool consisted of 65% males with a median age of 53 years. Of these, 45 donors (56%) were classified as extended criteria donors. Higher syndecan-1 levels correlated with the last creatinine levels before organ procurement (<em>R</em> = 0.32, <em>p</em> = 0.01) and were marginally higher in donors with acute kidney injury (<em>p</em> = 0.07). However, syndecan-1 levels were not associated with short-term outcomes in kidney recipients (renal function at 3 months).</div></div><div><h3>Conclusions</h3><div>The data suggests syndecan-1 could be a potential biomarker for assessing donor kidney quality, although its implications on recipient outcomes require further study. This pilot investigation underscores the importance of syndecan-1 in evaluating organ quality but highlights the necessity for more extensive research to validate these findings and explore their implications in transplant success.</div></div>\",\"PeriodicalId\":23246,\"journal\":{\"name\":\"Transplantation proceedings\",\"volume\":\"57 2\",\"pages\":\"Pages 187-193\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-01-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transplantation proceedings\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0041134524006924\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation proceedings","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041134524006924","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：与长期透析相比，肾移植仍然是终末期肾脏疾病的最佳治疗方法，可以改善生活质量，提高生存率。然而，尽管手术技术、免疫抑制方案和术后护理取得了进步，但在预测器官的状态和移植的长期结果方面仍然存在重大挑战。在影响移植物存活的诸多因素中，捐赠器官的质量起着至关重要的作用。人们一直需要准确可靠的生物标志物。Syndecan-1存在于内皮糖萼中，在全身性病理状态下以较高的速率进入血液。本研究的目的是评估血清syndecan-1水平作为评估供体肾脏质量的生物标志物的潜力，并研究其与供体特征和肾受体短期预后的相关性。材料和方法：我们调查了80名已故供者的血清syndecan-1水平，并将其与104名相应肾受体的供者特征和短期结果（定义为移植后第一周内需要透析和移植后3个月的肾功能-用血清肌酐水平评估）相关联。该单中心回顾性观察队列研究于2021年4月至12月进行。结果：供体池65%为男性，中位年龄53岁。其中，45名捐赠者（56%）被列为扩展标准捐赠者。较高的syndecan-1水平与器官获取前最后肌酐水平相关（R = 0.32, p = 0.01），急性肾损伤供者肌酐水平略高（p = 0.07）。然而，syndecan-1水平与肾受体的短期预后（3个月时的肾功能）无关。结论：数据表明syndecan-1可能是评估供体肾脏质量的潜在生物标志物，尽管其对受体预后的影响需要进一步研究。这项初步研究强调了syndecan-1在评估器官质量中的重要性，但也强调了更广泛的研究来验证这些发现并探索其在移植成功中的意义的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Syndecan-1 in the Serum of Deceased Kidney Donors as a Potential Biomarker of Kidney Function

Background

The process of kidney transplantation remains the optimal treatment for end-stage renal disease, offering improved quality of life and increased survival rates compared to long-term dialysis. However, despite advances in surgical techniques, immunosuppression regimens, and post-operative care, there are still significant challenges in predicting the organ's status and long-term outcomes of transplantation. Among the many factors that influence graft survival, the quality of the donated organ plays a fundamental role. There is an ongoing need for accurate and reliable biomarkers. Syndecan-1 is found in the endothelial glycocalyx and shed at a higher rate into the blood during systemic pathological conditions. The aim of this study is to evaluate the potential of serum syndecan-1 levels as a biomarker for assessing donor kidney quality and to investigate its correlation with donor characteristics and short-term outcomes in kidney recipients.

Material and Methods

We investigated serum syndecan-1 levels in 80 deceased donors and correlated them with donor characteristics and short-term outcomes (defined as delayed graft function - defined as the need for dialysis within the first week post-transplantation and renal function at 3 months post-transplantation - assessed using serum creatinine levels) in 104 corresponding kidney recipients. This single-center retrospective observational cohort study was conducted from April to December 2021.

Results

The donor pool consisted of 65% males with a median age of 53 years. Of these, 45 donors (56%) were classified as extended criteria donors. Higher syndecan-1 levels correlated with the last creatinine levels before organ procurement (R = 0.32, p = 0.01) and were marginally higher in donors with acute kidney injury (p = 0.07). However, syndecan-1 levels were not associated with short-term outcomes in kidney recipients (renal function at 3 months).

Conclusions

The data suggests syndecan-1 could be a potential biomarker for assessing donor kidney quality, although its implications on recipient outcomes require further study. This pilot investigation underscores the importance of syndecan-1 in evaluating organ quality but highlights the necessity for more extensive research to validate these findings and explore their implications in transplant success.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Transplantation proceedings 医学-免疫学

CiteScore

1.70

自引率

0.00%

发文量

502

审稿时长

60 days

期刊介绍： Transplantation Proceedings publishes several different categories of manuscripts, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. The first type of manuscripts consists of sets of papers providing an in-depth expression of the current state of the art in various rapidly developing components of world transplantation biology and medicine. These manuscripts emanate from congresses of the affiliated transplantation societies, from Symposia sponsored by the Societies, as well as special Conferences and Workshops covering related topics. Transplantation Proceedings also publishes several special sections including publication of Clinical Transplantation Proceedings, being rapid original contributions of preclinical and clinical experiences. These manuscripts undergo review by members of the Editorial Board. Original basic or clinical science articles, clinical trials and case studies can be submitted to the journal?s open access companion title Transplantation Reports.